Yüklüyor......
Intranasally administered peptidic viral fusion inhibitor protected hDPP4 transgenic mice from MERS-CoV infection
BACKGROUND: Middle East respiratory syndrome coronavirus (MERS-CoV), a new coronavirus that emerged in 2012, causes severe and fatal acute respiratory illness in man. Its high mortality (roughly 38%) has raised public fear worldwide, calling for the development of effective and safe therapeutics to...
Kaydedildi:
| Yayımlandı: | Lancet |
|---|---|
| Asıl Yazarlar: | , , , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Elsevier Ltd.
2015
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7159274/ https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(15)00625-X |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|